Buprenorphine-wafer for drug substitution therapy

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9763931
SERIAL NO

15135724

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • PURDUE PHARMA L.P.

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Heath, William Cambridge, GB 13 55
Holden, Timothy Cambridge, GB 8 39
Oksche, Alexander Limburg, DE 21 74
Prater, Derek A Cambridge, GB 15 615
Sackler, Richard S Greenwich, US 43 1431
Walden, Malcolm Cambridge, GB 27 315

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 19, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 19, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00